Loading...
XKRX
115450
Market cap481mUSD
Jun 12, Last price  
9,190.00KRW
Name

HLB Therapeutics Co Ltd

Chart & Performance

D1W1MN
XKRX:115450 chart
No data to show
P/E
P/S
12.04
EPS
Div Yield, %
Shrs. gr., 5y
8.37%
Rev. gr., 5y
-1.41%
Revenues
54.93b
+2.20%
17,710,432,25917,152,269,92543,584,676,45058,966,186,15842,929,780,55043,586,410,99542,402,741,73653,749,062,57054,931,940,880
Net income
-22.79b
L+890.07%
-5,200,341,731-4,815,732,8134,574,670,167-16,423,155,101-16,902,399,757-17,197,218,090-11,353,689,167-2,302,158,280-22,792,981,780
CFO
1.29b
-61.29%
-2,716,319,717-4,659,523,364-3,525,982,522-5,543,219,589-11,650,879,327-11,267,897,825-8,808,556,0733,326,877,4001,287,758,760
Earnings
Aug 12, 2025

Profile

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB Therapeutics Co.,Ltd. in December 2021. HLB Therapeutics Co.,Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.
URL
IPO date
Mar 26, 2010
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
54,931,941
2.20%
53,749,063
26.76%
42,402,742
-2.72%
Cost of revenue
54,218,839
57,284,369
45,206,850
Unusual Expense (Income)
NOPBT
713,102
(3,535,306)
(2,804,108)
NOPBT Margin
1.30%
Operating Taxes
(730)
(2,102,964)
Tax Rate
NOPAT
713,102
(3,535,306)
(701,145)
Net income
(22,792,982)
890.07%
(2,302,158)
-79.72%
(11,353,689)
-33.98%
Dividends
Dividend yield
Proceeds from repurchase of equity
9,523,751
12,947,506
(7,079)
BB yield
-1.03%
-4.12%
0.00%
Debt
Debt current
17,981,526
8,059,960
51,946,235
Long-term debt
6,022,570
2,708,822
184,737
Deferred revenue
Other long-term liabilities
649,476
522,938
851,984
Net debt
(58,556,922)
(78,105,041)
(30,089,989)
Cash flow
Cash from operating activities
1,287,759
3,326,877
(8,808,556)
CAPEX
(636,973)
(5,759,592)
(5,587,543)
Cash from investing activities
(35,457,253)
(20,159,921)
(41,930,362)
Cash from financing activities
28,394,436
(5,280,908)
(3,317,883)
FCF
(1,178,408)
13,621,685
(11,371,119)
Balance
Cash
37,772,802
31,309,022
61,885,533
Long term investments
44,788,215
57,564,801
20,335,428
Excess cash
79,814,420
86,186,370
80,100,824
Stockholders' equity
34,297,541
46,826,727
35,834,836
Invested Capital
147,169,010
135,237,422
145,126,929
ROIC
0.51%
ROCE
0.35%
EV
Common stock shares outstanding
79,096
71,664
129,604
Price
11,710.00
167.05%
4,385.00
-18.96%
5,410.63
-18.08%
Market cap
926,213,329
194.74%
314,245,386
-55.19%
701,241,284
81.64%
EV
892,060,001
247,193,190
682,559,308
EBITDA
8,805,323
4,944,020
(1,138,459)
EV/EBITDA
101.31
50.00
Interest
1,964,299
1,113,300
5,146,352
Interest/NOPBT
275.46%